Article
Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA
2 Jul 2021
Abstract excerpt
Liquid biopsy is a valuable precision oncology tool that is increasingly used as a non-invasive approach to identify biomarkers, detect resistance mutations, monitor disease burden, and identify early recurrence. The Tempus xF liquid biopsy assay is a 105-gene, hybrid-capture, next-generation sequencing (NGS) assay that detects single-nucleotide variants, insertions/deletions, copy number variants, and...
Topics
Join the communities discussing this publication.